Convexia describes itself as the world's first AI-maximalist pharma company, using autonomous agents to identify, evaluate, and commercialize pharmaceutical assets. Its stated capabilities include sourcing overlooked drug candidates, running computational biology assessments, analyzing market dynamics, simulating clinical trials, and identifying optimal commercial partners. The company buys drugs, runs clinical trials, and aims to sell them for profit. Founded in 2025 by Stanford CS grads Ayaan Parikh and Rahul Vijayan, Convexia was part of YC's Summer 2025 batch.
Convexia
ActiveThe world's first AI-maximalist pharma company
Total raised
$500K
1 round
Stage
Seed
Jan 2025
Team
1-10
since 2025
Pricing
—
Founded
2025
San Francisco, United States
Agent-ready
—
Autonomous agents for sourcing drug candidates
Computational biology assessment of assets
Market-dynamics analysis
Simulated clinical trials
Identification of optimal commercial partners
AI-driven asset evaluation and commercialization
Pipeline focused on overlooked drug candidates
AI-maximalist operating model for pharma
12/100
Early
MCP server
Public API
Webhooks
OAuth 2.0
SDKs
No public agent surfaces detected yet.
Jan 2025 Seed $500K ● Y Combinator
Capital network
$500K raised ·1 backer·10 network links
- Backers1
- Shared portfoliocompanies these backers also fund
- Extended networkfunds that co-invest alongside them
Pearl Health
AI value-based care platform for primary care providers
AI AnalyticsAI Healthcare
Commure
AI Healthcare
Innovaccer
AI Healthcare
Truveta
AI Healthcare
Terray Therapeutics
Generative AI and ultra-high-throughput chemistry for small-molecule drug discovery
AI HealthcareDrug Discovery
Genesis Molecular AI
Generative AI for small-molecule drug discovery
AI HealthcareDrug Discovery
- What is an 'AI-maximalist pharma company'?
- Convexia describes itself as the first such company, using autonomous agents to identify, evaluate, and commercialize pharmaceutical assets rather than relying primarily on manual processes.
- What does Convexia actually do?
- It sources overlooked drug candidates, runs computational biology assessments, analyzes market dynamics, simulates clinical trials, identifies commercial partners, and aims to buy, develop, and sell drugs for profit.
- Does it run real clinical trials?
- Convexia's model includes buying drugs and running clinical trials; its simulated trials inform decisions but real-world trials remain subject to standard regulatory requirements.
- Who founded Convexia?
- It was founded in 2025 by Stanford CS graduates Ayaan Parikh and Rahul Vijayan.
Discussion
Sign in to join the discussion.
Sign inExplore more around Convexia
Contextual paths to related AI startups, deals and rankings.